4D Molecular Shares Rise on FDA Designation for Wet AMD Drug
By Dean Seal
Shares of 4D Molecular Therapeutics rose after federal regulators granted regenerative medicine advanced therapy designation to its treatment for wet age-related macular degeneration.
The stock was up 5.7% at $20.13 in midday trading. Shares are still down about 9% year-to-date.
The clinical-stage biotherapeutics company said Thursday that the Food and Drug Administration granted the so-called RMAT designation to 4D-150 for intravitreal treatment of wed AMD.
The designation is based on 4D-150's potential to address unmet medical needs, the company said.
Chief Executive David Kirn said this was the first RMAT designation for an investigational treatment for wet AMD.
Write to Dean Seal at dean.seal@wsj.com
(END) Dow Jones Newswires
December 21, 2023 12:16 ET (17:16 GMT)
Copyright (c) 2023 Dow Jones & Company, Inc.-
After Earnings, Is Home Depot Stock a Buy, a Sell, or Fairly Valued?
-
After Earnings, Is Baidu Stock a Buy, a Sell, or Fairly Valued?
-
Why Stocks Are Hitting Record Highs—and What Could Send Them Back to Earth
-
5 Stocks to Buy While They’re Trading at Big Discounts
-
Markets Brief: Tech Stocks Lead Ahead of Nvidia Earnings
-
How Anti-Obesity Drugs Are Innovating the Healthcare Market
-
What’s Happening In the Markets This Week
-
Why Immigration Has Boosted Job Gains and the Economy
-
Nvidia Earnings: AI Demand Smashes Expectations Again
-
After Earnings, Is Walmart Stock a Buy, a Sell, or Fairly Valued?
-
Target Earnings: Margins Hold Up, but Top Line Constrained by Weak Discretionary Spending
-
Is Berkshire Hathaway’s Mystery Stock a Buy?
-
After Earnings, Is Uber Stock a Buy, a Sell, or Fairly Valued?
-
Lowe’s Earnings: Tumultuous Macro Weighs on Near-Term Results but Fails to Sway Our Long-Term View
-
Macy’s Earnings: Plan Taking Shape Despite Tough Environment
-
JPMorgan Investor Day: CEO Dimon Pushes Against More Stock Buybacks at Current Prices